#kp311 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #kp311, aggregated by home.social.
-
[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
-
Enhanced immune #evasion of #SARS-CoV-2 variants #KP311 and #XEC through N-terminal domain #mutations
Source: Lancet Infectious Diseases, Correspondence, {Excerpt} KP.3, a subvariant of JN.1, has rapidly emerged as the dominant strain of SARS-CoV-2 in several countries, and has been designated as a Variant Under Monitoring. Previous studies indicate that the unique Q493E substitution in KP.3 Spike glycoprotein enhances its receptor ACE2-binding affinity and immune…
-
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
#Impact of #JN1 #booster #vaccination on #neutralisation of #SARS-CoV-2 variants #KP311 and #XEC
Source: BioRxIV, {Excerpt} Conclusion Collectively, we found that the XEC S protein retains the ability to efficiently engage ACE2 and drive cell entry, although entry into Calu-3 lung cells was reduced. Both KP.3.1.1pp and XECpp were generally less well neutralised compared to JN.1pp, indicating elevated immune evasion. Importantly, JN.1-booster vaccination significantly…
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
Le dernier #variant d’ #Omicron majoritaire en #France mais peu virulent https://www.lemonde.fr/sciences/article/2024/08/30/le-dernier-variant-d-omicron-majoritaire-en-france-mais-peu-virulent_6299007_1650684.html
Depuis son apparition fin 2019, le virus du #Covid19 a muté régulièrement avec un dernier sous-variant, le #KP311, porteur de trois mutations qui le rendent plus contagieux.
-
[Correspondence] Virological #characteristics of the #SARS-CoV-2 #KP311 #variant https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00505-X/fulltext?rss=yes
SARS-CoV-2 #JN1 variant (#BA28611), arising from BA.2.86.1 with spike protein (S) substitution S:L455S, outcompeted previously predominant #XBB lineages by beginning of 2024. Subsequently, JN.1 subvariants including #KP2 (JN.1.11.1.2) & #KP3 (JN.1.11.1.3), which acquired additional S substitutions (eg, S:R346T, S:F456L, and S:Q493E) have emerged concurrently (appendix pp 19–20).2
-
[Correspondence] Virological #characteristics of the #SARS-CoV-2 #KP311 #variant https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00505-X/fulltext?rss=yes
SARS-CoV-2 #JN1 variant (#BA28611), arising from BA.2.86.1 with spike protein (S) substitution S:L455S, outcompeted previously predominant #XBB lineages by beginning of 2024. Subsequently, JN.1 subvariants including #KP2 (JN.1.11.1.2) & #KP3 (JN.1.11.1.3), which acquired additional S substitutions (eg, S:R346T, S:F456L, and S:Q493E) have emerged concurrently (appendix pp 19–20).2
-
[Correspondence] Virological #characteristics of the #SARS-CoV-2 #KP311 #variant https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00505-X/fulltext?rss=yes
SARS-CoV-2 #JN1 variant (#BA28611), arising from BA.2.86.1 with spike protein (S) substitution S:L455S, outcompeted previously predominant #XBB lineages by beginning of 2024. Subsequently, JN.1 subvariants including #KP2 (JN.1.11.1.2) & #KP3 (JN.1.11.1.3), which acquired additional S substitutions (eg, S:R346T, S:F456L, and S:Q493E) have emerged concurrently (appendix pp 19–20).2
-
[Correspondence] Virological #characteristics of the #SARS-CoV-2 #KP311 #variant https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00505-X/fulltext?rss=yes
SARS-CoV-2 #JN1 variant (#BA28611), arising from BA.2.86.1 with spike protein (S) substitution S:L455S, outcompeted previously predominant #XBB lineages by beginning of 2024. Subsequently, JN.1 subvariants including #KP2 (JN.1.11.1.2) & #KP3 (JN.1.11.1.3), which acquired additional S substitutions (eg, S:R346T, S:F456L, and S:Q493E) have emerged concurrently (appendix pp 19–20).2
-
#Pemivibart is less active against recent #SARS-CoV-2 #JN1 #sublineages http://biorxiv.org/cgi/content/short/2024.08.12.607496v1?rss=1
Pemivibart neutralized both JN.1 and #KP2 in vitro with comparable activity, whereas its potency was decreased slightly against #LB1, #KP23, and #KP3 but substantially against #KP311. Critically, the 50% inhibitory concentration of pemivibart against KP.3.1.1 was ~6 g/mL, or ~32.7 fold higher than that of JN.1.
-
An upcoming #vaccine from the biotech co Novavax will target #JN1, a #coronavirus #variant that accounted for the bulk of cases in the #UnitedStates this winter. The Pfizer & Moderna shots coming this fall will target #KP2, a newer offshoot of JN.1 that’s been circulating this summer. The #variants responsible for the largest share of cases in the #US right now, #KP3 & #KP311, are closely related to KP.2 & JN.1.
-
#Italy, Summer #Covid19 #wave: more than 13,000 new cases - a 50% rise compared last week, #KP311 variant proportion increase, https://www.ilfattoquotidiano.it/2024/07/26/covid-oltre-13mila-nuovi-casi-il-50-in-piu-in-una-settimana-e-cresce-la-variante-kp-3-1-1-che-puo-avvantaggiare-il-virus/7637247/
-
#Virological #characteristics of the #SARS-CoV-2 #KP311 #variant http://biorxiv.org/cgi/content/short/2024.07.16.603835v1?rss=1
KP.3.1.1 exhibited a higher Re, higher pseudovirus infectivity, & higher neutralization #evasion than KP.3. These results align with our recent report that #JN1 subvariants with S:S31del (eg KP.2.3 & LB.1) exhibited enhanced Re and immune evasion compared to other JN.1 subvariants without S:S31del (eg JN.1, KP.2, & KP.3), highlighting evolutionary significance of S:S31del in JN.1 lineages.
-
#Virological #characteristics of the #SARS-CoV-2 #KP311 #variant http://biorxiv.org/cgi/content/short/2024.07.16.603835v1?rss=1
KP.3.1.1 exhibited a higher Re, higher pseudovirus infectivity, & higher neutralization #evasion than KP.3. These results align with our recent report that #JN1 subvariants with S:S31del (eg KP.2.3 & LB.1) exhibited enhanced Re and immune evasion compared to other JN.1 subvariants without S:S31del (eg JN.1, KP.2, & KP.3), highlighting evolutionary significance of S:S31del in JN.1 lineages.
-
#Virological #characteristics of the #SARS-CoV-2 #KP311 #variant http://biorxiv.org/cgi/content/short/2024.07.16.603835v1?rss=1
KP.3.1.1 exhibited a higher Re, higher pseudovirus infectivity, & higher neutralization #evasion than KP.3. These results align with our recent report that #JN1 subvariants with S:S31del (eg KP.2.3 & LB.1) exhibited enhanced Re and immune evasion compared to other JN.1 subvariants without S:S31del (eg JN.1, KP.2, & KP.3), highlighting evolutionary significance of S:S31del in JN.1 lineages.
-
#Virological #characteristics of the #SARS-CoV-2 #KP311 #variant http://biorxiv.org/cgi/content/short/2024.07.16.603835v1?rss=1
KP.3.1.1 exhibited a higher Re, higher pseudovirus infectivity, & higher neutralization #evasion than KP.3. These results align with our recent report that #JN1 subvariants with S:S31del (eg KP.2.3 & LB.1) exhibited enhanced Re and immune evasion compared to other JN.1 subvariants without S:S31del (eg JN.1, KP.2, & KP.3), highlighting evolutionary significance of S:S31del in JN.1 lineages.
-
#Virological #characteristics of the #SARS-CoV-2 #KP311 #variant http://biorxiv.org/cgi/content/short/2024.07.16.603835v1?rss=1
KP.3.1.1 exhibited a higher Re, higher pseudovirus infectivity, & higher neutralization #evasion than KP.3. These results align with our recent report that #JN1 subvariants with S:S31del (eg KP.2.3 & LB.1) exhibited enhanced Re and immune evasion compared to other JN.1 subvariants without S:S31del (eg JN.1, KP.2, & KP.3), highlighting evolutionary significance of S:S31del in JN.1 lineages.
